Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 799 results for "Ibrutinib"

Pharmacyclics' Imbruvica gets European approval to treat two blood cancers
Pharmaceutical Business Review

PHARMACYCLICS : IMBRUVICA® ibrutinib Supplemental New Drug Ap...

By a News Reporter-Staff News Editor at Biotech Week -- Janssen Research & Development, LLC (" Janssen ") announced the submission of a supplemental New Drug Application (sNDA) for IMBRUVICA(®) (ibrutinib) to the U.S. Food and Drug Administration ... 4 Traders, 21 hours ago

3 images for "Ibrutinib"

OncLive, 1 week ago
OncLive, 2 weeks ago
British Journal of Haematology, 3 weeks ago

IMBRUVICA (ibrutinib) ya está aprobado en Europa para el tratamiento de dos cánceres sanguíneos

SCHAFFHAUSEN, Suiza, 20 de octubre de 2014 /PRNewswire/ --Pharmacyclics Switzerland GmbH, una filial de Pharmacyclics, Inc. (NASDAQ: PCYC ), ha anunciado hoy que la Comisión Europea (CE) ha concedido una autorización de marketing para IMBRUVICA ...
 PR Newswire1 week ago La Comisión Europea aprueba IMBRUVICA para dos cánceres sanguíneos  PR Newswire1 week ago

New Chronic Lymphocytic Leukemia Findings Has Been Reported by Investigators at Pharmacyclics Inc. (Ibrutinib inhibits BCR and NF-kappa B signaling...

New Chronic Lymphocytic Leukemia Findings Has Been Reported by Investigators at Pharmacyclics Inc. (Ibrutinib inhibits BCR and NF-kappa B signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL) By a News ...
 4 Traders22 hours ago VIDEO: Are chemo-free regimens possible for CLL?  Oncology Report1 month ago Data from Pharmacyclics Inc. Advance Knowledge in Chronic Lymphocytic Leukemia (Kinetics of CLL cells in tissues and blood during therapy with the...  4 Traders22 hours ago Entering the Era of Targeted Therapy for Chronic Lymphocytic Leukemia: Impact on the Practicing Clinician  Journal of Clinical Oncology3 weeks ago
Pettinga Financial Advisors

BMS' PD-1 Inhibitor, Nivolumab, to be Evaluated With Jansenn's Ibrutinib in NHL

Bristol-Myers Squibb Company (NYSE:BMY), Pharmacyclics, Inc. (NASDAQ:PCYC), and Janssen Research & Development, LLC announced today they have entered into a clinical trial collaboration agreement to evaluate the safety, tolerability and preliminary ...
 American Journal of Managed Care2 weeks ago Bristol-Myers Squibb, Pharmacyclics and Janssen Announce Clinical Collaboration  Technology Networks2 weeks ago Bristol-Myers Squibb Posts Third Quarter Results  Individual.com1 day ago Bristol-Myers Squibb Releases 3Q 2014 Financial Results  Individual.com1 day ago

Ibrutinib ameliorates chronic graft-versus-host disease in mice

Ratings require JavaScript to be enabled. Hematopoietic stem cells (HSCs) can differentiate into all types of blood cells, including red blood cells and immune cells. While HSC transplantation can be life saving for patients with ...
 Medical News Today3 weeks ago B and T cell-targeting drug ameliorates chronic graft-versus-host disease in mice  EurekAlert!4 weeks ago

MCL: Study Identifies Rational Drug Combinations That May Overcome Resistance to Ibrutinib

Oncology Times: doi: 10.1097/01.COT.0000454180.31698.23 News SELINA CHEN-KIANG, PHD Image Tools Genomic analyses of tumor and healthy tissue from patients with mantle cell lymphoma (MCLs) that do not respond to ...
 Oncology Times1 month ago John Byrd Joins OT as Clinical Advisory Editor  Oncology Times1 month ago

Study identifies potential drug combination for mantle cell lymphoma and chronic lymphocytic leukaemia

Using the molecularly targeted drug ibrutinib (Imbruvica) together with the investigational anticancer agent ABT-199 may improve outcomes for patients with mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL), according to preclinical ...
 Ecancer Medicalscience1 month ago

Orphan drug market forecast to reach $176 billion by 2020

In 2020, orphan drugs are expected to account for 19% of the total share of prescription drug sales excluding generics, reaching $176 billion in annual sales, according to the new EvaluatePharma Orphan Drug Report 2014 from market intelligence firm ...
 Pharma Letter1 hour ago
Pharma Letter

Non-Hodgkin lymphoma market to grow to $9.2 billion

The non-Hodgkin lymphoma (NHL) market will be worth $9.2 billion by 2020, according to new research. This is up from $5.6 billion in 2013 at a modest compound annual growth rate (CAGR) of 7.4%. This growth will be driven by the expected launch of ...
 Pharma Letter21 hours ago NHL Market (Non-Hodgkin Lymphoma Therapeutics) Worth $9.2 Billion by 2020  Wall Street Select1 day ago APAC NHL Treatment Market to Reach US$1.7B by 2020  PharmaAsia1 month ago Japan's Non-Hodgkin Lymphoma Market to Top $1 Billion by 2020  Pharmaceutical Executive1 month ago

UPDATE: H.C. Wainwright Initiates Coverage On TG Therapeutics On Significant Long-Term Upside

In a report published Monday, H.C. Wainwright analyst Reni Benjamin initiated coverage on TG Therapeutics (NASDAQ: TGTX) with a Buy rating and $17.00 price target. In the report, H.C. Wainwright noted, We are initiating coverage of TG Therapeutics ...
 Benzinga.com3 days ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Get updated on latest news & your favorite topics right in your inbox!
More     Less